Nykredit A/S’s 10x Genomics TXG Stock Holding History

Nykredit A/S’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$126K	Buy	+3,277	New	+$85.9K	﹤0.01%	1225

Other funds holding TXG

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nykredit A/S's TXG Position: Q2 2026 in Review

Nykredit A/S opened a new position in 10x Genomics (TXG) in Q2 2026: 3,277 shares worth $126K. The stake represents ﹤0.01% of the portfolio and ranks #1225 among its holdings.

286 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Nykredit A/S held 3,277 shares of 10x Genomics worth $126K as of Q2 2026.
10x Genomics was a new Nykredit A/S position in Q2 2026.
10x Genomics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1225 holding.
286 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.